{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:17:33Z","timestamp":1791494253653,"version":"4.3.4"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02319-9","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:13:24Z","timestamp":1776651204000},"page":"887-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of \u03b2-Blockers in the Evolving Treatment Landscape of Resistant Hypertension"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-3686","authenticated-orcid":false,"given":"Stefano","family":"Masi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6107-3356","authenticated-orcid":false,"given":"Rosa Maria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7081-4881","authenticated-orcid":false,"given":"Sofie","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-5018","authenticated-orcid":false,"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5002-3070","authenticated-orcid":false,"given":"Stefano","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-211X","authenticated-orcid":false,"given":"Reinhold","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"12","key":"2319_CR1","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"38","key":"2319_CR2","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"issue":"10","key":"2319_CR3","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","volume":"82","author":"DW Jones","year":"2025","unstructured":"Writing Committee Members, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212\u2013316. https:\/\/doi.org\/10.1161\/HYP.0000000000000249.","journal-title":"Hypertension"},{"issue":"1","key":"2319_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15420\/ecr.2016:1:2","volume":"11","author":"CP Tsioufis","year":"2016","unstructured":"Tsioufis CP, Kasiakogias A, Tousoulis D. Clinical diagnosis and management of resistant hypertension. Eur Cardiol. 2016;11(1):12\u20137. https:\/\/doi.org\/10.15420\/ecr.2016:1:2.","journal-title":"Eur Cardiol"},{"key":"2319_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","volume":"126","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1\u201315. https:\/\/doi.org\/10.1016\/j.ejim.2024.05.033.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"2319_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98\u2013105. https:\/\/doi.org\/10.1136\/heartjnl-2018-313599.","journal-title":"Heart"},{"issue":"22","key":"2319_CR7","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1136\/heartjnl-2022-321730","volume":"110","author":"M Camafort","year":"2024","unstructured":"Camafort M, Kreutz R, Cho MC. Diagnosis and management of resistant hypertension. Heart. 2024;110(22):1336\u201342. https:\/\/doi.org\/10.1136\/heartjnl-2022-321730.","journal-title":"Heart"},{"issue":"10","key":"2319_CR8","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/imj.16189","volume":"53","author":"RJ Chan","year":"2023","unstructured":"Chan RJ, Helmeczi W, Hiremath SS. Revisiting resistant hypertension: a comprehensive review. Intern Med J. 2023;53(10):1739\u201351. https:\/\/doi.org\/10.1111\/imj.16189.","journal-title":"Intern Med J"},{"issue":"6","key":"2319_CR9","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1161\/HYPERTENSIONAHA.121.18198","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H, Investigators network. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP study. Hypertension. 2021;78(6):1781\u201390. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18198.","journal-title":"Hypertension"},{"issue":"2","key":"2319_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/HJH.0000000000000023","volume":"32","author":"C Tsioufis","year":"2014","unstructured":"Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014;32(2):415\u201322. https:\/\/doi.org\/10.1097\/HJH.0000000000000023.","journal-title":"J Hypertens"},{"issue":"10","key":"2319_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/eurjpc\/zwad066","volume":"30","author":"JE Ebinger","year":"2023","unstructured":"Ebinger JE, Kauko A, FinnGen, Bello NA, Cheng S, Niiranen T. Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry. Eur J Prev Cardiol. 2023;30(10):960\u20138. https:\/\/doi.org\/10.1093\/eurjpc\/zwad066.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"2319_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jch.14701","volume":"25","author":"G Bakris","year":"2023","unstructured":"Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023;25(8):737\u201347. https:\/\/doi.org\/10.1111\/jch.14701.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2319_CR13","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.51","volume":"19","author":"G Buso","year":"2024","unstructured":"Buso G, Agabiti-Rosei C, Lemoli M, Corvini F, Muiesan ML. The global burden of resistant hypertension and potential treatment options. Eur Cardiol. 2024;19:e07. https:\/\/doi.org\/10.15420\/ecr.2023.51.","journal-title":"Eur Cardiol"},{"issue":"9","key":"2319_CR14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1136\/heart.89.9.1104","volume":"89","author":"J Mayet","year":"2003","unstructured":"Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart. 2003;89(9):1104\u20139. https:\/\/doi.org\/10.1136\/heart.89.9.1104.","journal-title":"Heart"},{"issue":"5","key":"2319_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/00004872-200305000-00016","volume":"21","author":"BL Rayner","year":"2003","unstructured":"Rayner BL, Owen EP, King JA, Soule SG, Vreede H, Opie LH, et al. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. J Hypertens. 2003;21(5):921\u20136. https:\/\/doi.org\/10.1097\/00004872-200305000-00016.","journal-title":"J Hypertens"},{"issue":"9","key":"2319_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11906-015-0583-8","volume":"17","author":"N El Rouby","year":"2015","unstructured":"El Rouby N, Cooper-DeHoff RM. Genetics of resistant hypertension: a novel pharmacogenomics phenotype. Curr Hypertens Rep. 2015;17(9):583. https:\/\/doi.org\/10.1007\/s11906-015-0583-8.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"2319_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11906-023-01282-0","volume":"26","author":"JM Flack","year":"2024","unstructured":"Flack JM, Buhnerkempe MG, Moore KT. Resistant hypertension: disease burden and emerging treatment options. Curr Hypertens Rep. 2024;26(5):183\u201399. https:\/\/doi.org\/10.1007\/s11906-023-01282-0.","journal-title":"Curr Hypertens Rep"},{"issue":"sup1","key":"2319_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/03007995.2024.2305248","volume":"40","author":"G Grassi","year":"2024","unstructured":"Grassi G, Drager LF. Sympathetic overactivity, hypertension and cardiovascular disease: state of the art. Curr Med Res Opin. 2024;40(sup1):5\u201313. https:\/\/doi.org\/10.1080\/03007995.2024.2305248.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2319_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/HYPERTENSIONAHA.123.17959","volume":"81","author":"MA Bailey","year":"2024","unstructured":"Bailey MA, Dhaun N. Salt sensitivity: causes, consequences, and recent advances. Hypertension. 2024;81(3):476\u201389. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.17959.","journal-title":"Hypertension"},{"issue":"2","key":"2319_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.124.325439","volume":"136","author":"AL Mutchler","year":"2025","unstructured":"Mutchler AL, Haynes AP, Saleem M, Jamison S, Khan MM, Ertuglu L, et al. Epigenetic regulation of innate and adaptive immune cells in salt-sensitive hypertension. Circ Res. 2025;136(2):232\u201354. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325439.","journal-title":"Circ Res"},{"key":"2319_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2023.103133","volume":"250","author":"MM Gauthier","year":"2023","unstructured":"Gauthier MM, Hayoz S, Banek CT. Neuroimmune interplay in kidney health and disease: role of renal nerves. Auton Neurosci. 2023;250:103133. https:\/\/doi.org\/10.1016\/j.autneu.2023.103133.","journal-title":"Auton Neurosci"},{"issue":"2","key":"2319_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.25719","volume":"83","author":"JE Ebinger","year":"2026","unstructured":"Ebinger JE, Kauko A, Vaura F, Hage P, Sundstrom J, FinnGen, et al. GWAS and replication analysis of apparent treatment-resistant hypertension. Hypertension. 2026;83(2):e25719. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.125.25719.","journal-title":"Hypertension"},{"issue":"2","key":"2319_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/cpt.2934","volume":"114","author":"K Yamazaki","year":"2023","unstructured":"Yamazaki K, Terao C, Takahashi A, Kamatani Y, Matsuda K, Asai S, et al. Genome-wide association studies categorized by class of antihypertensive drugs reveal complex pathogenesis of hypertension with drug resistance. Clin Pharmacol Ther. 2023;114(2):393\u2013403. https:\/\/doi.org\/10.1002\/cpt.2934.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2319_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010113","volume":"26","author":"GL N\u00e1dasy","year":"2024","unstructured":"N\u00e1dasy GL, Balla A, D\u00f6rnyei G, Hunyady L, Szekeres M. Direct vascular effects of Angiotensin II (a systematic short review). Int J Mol Sci. 2024;26(1):113. https:\/\/doi.org\/10.3390\/ijms26010113.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2319_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10286-018-0572-5","volume":"29","author":"AJ Miller","year":"2019","unstructured":"Miller AJ, Arnold AC. The Renin-Angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. Clin Auton Res. 2019;29(2):231\u201343. https:\/\/doi.org\/10.1007\/s10286-018-0572-5.","journal-title":"Clin Auton Res"},{"issue":"1","key":"2319_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/15701611113119990140","volume":"12","author":"AJ Manolis","year":"2014","unstructured":"Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):4\u201315. https:\/\/doi.org\/10.2174\/15701611113119990140.","journal-title":"Curr Vasc Pharmacol"},{"issue":"6","key":"2319_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(18)30071-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2319_CR28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","volume":"116","author":"L Te Riet","year":"2015","unstructured":"Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303587.","journal-title":"Circ Res"},{"issue":"11","key":"2319_CR29","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41440-022-01009-9","volume":"45","author":"AG Lopez","year":"2022","unstructured":"Lopez AG, Louiset E, Lefebvre H. Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion. Hypertens Res. 2022;45(11):1832\u20134. https:\/\/doi.org\/10.1038\/s41440-022-01009-9.","journal-title":"Hypertens Res"},{"issue":"8","key":"2319_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/HYPERTENSIONAHA.125.24749","volume":"82","author":"G Grassi","year":"2025","unstructured":"Grassi G, Quarti-Trevano F, Cuspidi C, Sanidas E, Mancia G, Thomopoulos C. Sympathetic overactivation in the resistant hypertensive phenotype: a meta-analysis of published studies. Hypertension. 2025;82(8):1346\u201354. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.125.24749.","journal-title":"Hypertension"},{"issue":"3","key":"2319_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ijcard.2014.09.138","volume":"177","author":"G Grassi","year":"2014","unstructured":"Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177(3):1020\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.138.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2319_CR32","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/HJH.0000000000002661","volume":"39","author":"G Grassi","year":"2021","unstructured":"Grassi G, Biffi A, Seravalle G, Bertoli S, Airoldi F, Corrao G, et al. Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. J Hypertens. 2021;39(3):408\u201316. https:\/\/doi.org\/10.1097\/HJH.0000000000002661.","journal-title":"J Hypertens"},{"issue":"4","key":"2319_CR33","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/HYPERTENSIONAHA.119.13009","volume":"74","author":"R Dell'Oro","year":"2019","unstructured":"Dell\u2019Oro R, Quarti-Trevano F, Seravalle G, Zanchettin F, Bertoli S, Airoldi F, et al. Sympathetic nerve traffic and arterial baroreflex function in apparent drug-resistant hypertension. Hypertension. 2019;74(4):903\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13009.","journal-title":"Hypertension"},{"issue":"6","key":"2319_CR34","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ajh\/hpx018","volume":"30","author":"EJ Howden","year":"2017","unstructured":"Howden EJ, East C, Lawley JS, Stickford ASL, Verhees M, Fu Q, et al. Integrative blood pressure response to upright tilt post renal denervation. Am J Hypertens. 2017;30(6):632\u201341. https:\/\/doi.org\/10.1093\/ajh\/hpx018.","journal-title":"Am J Hypertens"},{"issue":"9","key":"2319_CR35","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2215\/CJN.01220215","volume":"10","author":"G Grassi","year":"2015","unstructured":"Grassi G, Seravalle G, Trevano FQ, Spaziani D, Scalise F, Auguadro C, et al. Asymmetric and symmetric dimethylarginine and sympathetic nerve traffic after renal denervation in patients with resistant hypertension. Clin J Am Soc Nephrol. 2015;10(9):1560\u20137. https:\/\/doi.org\/10.2215\/CJN.01220215.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2319_CR36","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1097\/HJH.0b013e3283622e58","volume":"31","author":"D Hering","year":"2013","unstructured":"Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens. 2013;31(9):1893\u2013900. https:\/\/doi.org\/10.1097\/HJH.0b013e3283622e58.","journal-title":"J Hypertens"},{"issue":"2","key":"2319_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.111.00194","volume":"61","author":"D Hering","year":"2013","unstructured":"Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457\u201364. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.00194.","journal-title":"Hypertension"},{"issue":"1","key":"2319_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.113.03098","volume":"64","author":"D Hering","year":"2014","unstructured":"Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014;64(1):118\u201324. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.03098.","journal-title":"Hypertension"},{"issue":"11","key":"2319_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259826","volume":"16","author":"M van Kleef","year":"2021","unstructured":"van Kleef M, Heusser K, Diedrich A, Oey PL, Tank J, Jordan J, et al. Endovascular baroreflex amplification and the effect on sympathetic nerve activity in patients with resistant hypertension: a proof-of-principle study. PLoS ONE. 2021;16(11):e0259826. https:\/\/doi.org\/10.1371\/journal.pone.0259826.","journal-title":"PLoS ONE"},{"issue":"2","key":"2319_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10286-023-00927-z","volume":"33","author":"R Dell'Oro","year":"2023","unstructured":"Dell\u2019Oro R, Quarti-Trevano F, Seravalle G, Cuspidi C, Grassi G. Differential effects of renal denervation on skin and muscle sympathetic nerve traffic in resistant and uncontrolled hypertension. Clin Auton Res. 2023;33(2):93\u2013100. https:\/\/doi.org\/10.1007\/s10286-023-00927-z.","journal-title":"Clin Auton Res"},{"issue":"6","key":"2319_CR41","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1161\/HYPERTENSIONAHA.112.201186","volume":"60","author":"J Brinkmann","year":"2012","unstructured":"Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60(6):1485\u201390. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.201186.","journal-title":"Hypertension"},{"issue":"2","key":"2319_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00540","volume":"61","author":"F Mahfoud","year":"2013","unstructured":"Mahfoud F, Bohm M, Rump LC, Vonend O, Schmieder RE, Kintscher U. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2013;61(2):e17. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.00540.","journal-title":"Hypertension"},{"issue":"8","key":"2319_CR43","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/ndt\/gfx200","volume":"32","author":"G Seravalle","year":"2017","unstructured":"Seravalle G, D\u2019Arrigo G, Tripepi G, Mallamaci F, Brambilla G, Mancia G, et al. Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. Nephrol Dial Transpl. 2017;32(8):1351\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfx200.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"2319_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2014.06.021","volume":"176","author":"EE Vink","year":"2014","unstructured":"Vink EE, Verloop WL, Siddiqi L, van Schelven LJ, Oey LP, Blankestijn PJ. The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients. Int J Cardiol. 2014;176(1):8\u201312. https:\/\/doi.org\/10.1016\/j.ijcard.2014.06.021.","journal-title":"Int J Cardiol"},{"issue":"5","key":"2319_CR45","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000244688.45472.95","volume":"48","author":"L Pojoga","year":"2006","unstructured":"Pojoga L, Kolatkar NS, Williams JS, Perlstein TS, Jeunemaitre X, Brown NJ, et al. Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Hypertension. 2006;48(5):892\u2013900. https:\/\/doi.org\/10.1161\/01.HYP.0000244688.45472.95.","journal-title":"Hypertension"},{"key":"2319_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115386","volume":"208","author":"N D\u00edaz-Morales","year":"2023","unstructured":"D\u00edaz-Morales N, Baranda-Alonso EM, Mart\u00ednez-Salgado C, L\u00f3pez-Hern\u00e1ndez FJ. Renal sympathetic activity: a key modulator of pressure natriuresis in hypertension. Biochem Pharmacol. 2023;208:115386. https:\/\/doi.org\/10.1016\/j.bcp.2022.115386.","journal-title":"Biochem Pharmacol"},{"key":"2319_CR47","doi-asserted-by":"publisher","first-page":"1608423","DOI":"10.3389\/fgene.2025.1608423","volume":"16","author":"JN Katsukunya","year":"2025","unstructured":"Katsukunya JN, Naicker R, Soko ND, Blom D, Sinxadi P, Chimusa ER, et al. NOS3 rs3918188C>A is associated with susceptibility to resistant hypertension while CES1 genetic variation was not associated with resistant hypertension among South Africans. Front Genet. 2025;16:1608423. https:\/\/doi.org\/10.3389\/fgene.2025.1608423.","journal-title":"Front Genet"},{"issue":"9","key":"2319_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091789","volume":"14","author":"K Musialik","year":"2022","unstructured":"Musialik K, Miller-Kasprzak E, Walczak M, Markuszewski L, Bogdanski P. The association between serum resistin level, resistin (-420c\/g) single nucleotide variant, and markers of endothelial dysfunction, including salt taste preference in hypertensive patients. Nutrients. 2022;14(9):1789. https:\/\/doi.org\/10.3390\/nu14091789.","journal-title":"Nutrients"},{"issue":"2","key":"2319_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41581-025-01020-6","volume":"22","author":"G Stolting","year":"2026","unstructured":"Stolting G, Tran Vo KN, Haus J, Scholl UI. The genetics of hypertension. Nat Rev Nephrol. 2026;22(2):137\u201351. https:\/\/doi.org\/10.1038\/s41581-025-01020-6.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2319_CR50","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.121.18776","volume":"79","author":"RS Vasan","year":"2022","unstructured":"Vasan RS, Pan S, Xanthakis V, Beiser A, Larson MG, Seshadri S, et al. Arterial stiffness and long-term risk of health outcomes: the Framingham heart study. Hypertension. 2022;79(5):1045\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18776.","journal-title":"Hypertension"},{"issue":"7","key":"2319_CR51","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacc.2013.09.063","volume":"63","author":"Y Ben-Shlomo","year":"2014","unstructured":"Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.063.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2319_CR52","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","volume":"78","author":"G Jia","year":"2021","unstructured":"Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78(5):1197\u2013205. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17981.","journal-title":"Hypertension"},{"issue":"8","key":"2319_CR53","doi-asserted-by":"publisher","first-page":"42","DOI":"10.18087\/cardio.2023.8.n2468","volume":"63","author":"MA Manukyan","year":"2023","unstructured":"Manukyan MA, Falkovskaya AY, Zyubanova IV, Solonskaya EI, Lichikaki VA, Ryabova TR, et al. Renal hemodynamics in patients with resistant hypertension and type 2 diabetes mellitus. Kardiologiia. 2023;63(8):42\u20139. https:\/\/doi.org\/10.18087\/cardio.2023.8.n2468.","journal-title":"Kardiologiia"},{"issue":"10","key":"2319_CR54","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/jch.13669","volume":"21","author":"M Tadic","year":"2019","unstructured":"Tadic M, Cuspidi C. Obesity and resistant hypertension: never ending story. J Clin Hypertens (Greenwich). 2019;21(10):1516\u20138. https:\/\/doi.org\/10.1111\/jch.13669.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"2319_CR55","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1080\/00325481.2023.2216987","volume":"135","author":"G G\u00f6kalp","year":"2023","unstructured":"G\u00f6kalp G, \u00d6zbeyaz NB. The relationship between visceral adipose index and resistant hypertension in people living with diabetes. Postgrad Med. 2023;135(5):524\u20139. https:\/\/doi.org\/10.1080\/00325481.2023.2216987.","journal-title":"Postgrad Med"},{"issue":"11","key":"2319_CR56","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1038\/s41440-024-01852-y","volume":"47","author":"K Shiina","year":"2024","unstructured":"Shiina K. Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategy. Hypertens Res. 2024;47(11):3085\u201398. https:\/\/doi.org\/10.1038\/s41440-024-01852-y.","journal-title":"Hypertens Res"},{"issue":"7","key":"2319_CR57","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11739-023-03376-8","volume":"18","author":"S Romano","year":"2023","unstructured":"Romano S, Rigon G, Albrigi M, Tebaldi G, Sartorio A, Cristin L, et al. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. a population-based observational study. Intern Emerg Med. 2023;18(7):1951\u20139. https:\/\/doi.org\/10.1007\/s11739-023-03376-8.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"2319_CR58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ajh\/hpad084","volume":"37","author":"E Jafari","year":"2024","unstructured":"Jafari E, Cooper-DeHoff RM, Effron MB, Hogan WR, McDonough CW. Characteristics and predictors of apparent treatment-resistant hypertension in real-world populations using electronic health record-based data. Am J Hypertens. 2024;37(1):60\u20138. https:\/\/doi.org\/10.1093\/ajh\/hpad084.","journal-title":"Am J Hypertens"},{"issue":"5","key":"2319_CR59","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/jch.14791","volume":"26","author":"G Bakris","year":"2024","unstructured":"Bakris G, Lin PP, Xu C, Chen C, Ashton V, Singhal M. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods. J Clin Hypertens (Greenwich). 2024;26(5):500\u201313. https:\/\/doi.org\/10.1111\/jch.14791.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2319_CR60","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622\u201332. https:\/\/doi.org\/10.1038\/ki.2015.142.","journal-title":"Kidney Int"},{"issue":"6","key":"2319_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension"},{"issue":"18","key":"2319_CR62","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2025;86(18):1567\u2013678. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2319_CR63","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/jama.2025.5129","volume":"333","author":"CJ Lee","year":"2025","unstructured":"Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs amiloride for resistant hypertension: a randomized clinical trial. JAMA. 2025;333(23):2073\u201382. https:\/\/doi.org\/10.1001\/jama.2025.5129.","journal-title":"JAMA"},{"issue":"10","key":"2319_CR64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.rec.2019.04.006","volume":"72","author":"E Oliver","year":"2019","unstructured":"Oliver E, Mayor F Jr., D\u2019Ocon P. Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed). 2019;72(10):853\u201362. https:\/\/doi.org\/10.1016\/j.rec.2019.04.006.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2319_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-030-57401-7_11","volume-title":"Encyclopedia of molecular pharmacology","author":"R Kreutz","year":"2021","unstructured":"Kreutz R, Algharably EAH. Antihypertensive drugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology. Cham: Springer; 2021. p. 165\u201374."},{"key":"2319_CR66","doi-asserted-by":"publisher","unstructured":"Bachmakov IE. FAN, Denisova VE. Beta-blockers and chronic kidney disease: a literature review (in Russ.). Kachestvennaya Klinicheskaya Praktika [Good Clin Pract]. 2023;4:68\u201377. https:\/\/doi.org\/10.37489\/2588-0519-2023-4-68-77","DOI":"10.37489\/2588-0519-2023-4-68-77"},{"key":"2319_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/919256","volume":"2014","author":"H Tomiyama","year":"2014","unstructured":"Tomiyama H, Yamashina A. Beta-blockers in the management of hypertension and\/or chronic kidney disease. Int J Hypertens. 2014;2014:919256. https:\/\/doi.org\/10.1155\/2014\/919256.","journal-title":"Int J Hypertens"},{"issue":"sup1","key":"2319_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/03007995.2024.2318058","volume":"40","author":"S Taddei","year":"2024","unstructured":"Taddei S, Tsabedze N, Tan RS. \u03b2-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Curr Med Res Opin. 2024;40(sup1):15\u201323. https:\/\/doi.org\/10.1080\/03007995.2024.2318058.","journal-title":"Curr Med Res Opin"},{"issue":"sup1","key":"2319_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/03007995.2024.2317433","volume":"40","author":"HP Marti","year":"2024","unstructured":"Marti HP, Pav\u00eda L\u00f3pez AA, Schwartzmann P. Safety and tolerability of beta-blockers: importance of cardioselectivity. Curr Med Res Opin. 2024;40(sup1):55\u201362. https:\/\/doi.org\/10.1080\/03007995.2024.2317433.","journal-title":"Curr Med Res Opin"},{"key":"2319_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/IJNRD.S414774","volume":"16","author":"I Haddiya","year":"2023","unstructured":"Haddiya I, Valoti S. Current knowledge of beta-blockers in chronic hemodialysis patients. Int J Nephrol Renovasc Dis. 2023;16:223\u201330. https:\/\/doi.org\/10.2147\/IJNRD.S414774.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"6","key":"2319_CR71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/1060028013519591","volume":"48","author":"TL Ripley","year":"2014","unstructured":"Ripley TL, Saseen JJ. Beta-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014;48(6):723\u201333. https:\/\/doi.org\/10.1177\/1060028013519591.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2319_CR72","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","volume":"70","author":"GL Bakris","year":"2006","unstructured":"Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905\u201313. https:\/\/doi.org\/10.1038\/sj.ki.5001835.","journal-title":"Kidney Int"},{"issue":"5","key":"2319_CR73","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1161\/HYPERTENSIONAHA.120.16590","volume":"77","author":"TG Riemer","year":"2021","unstructured":"Riemer TG, Villagomez Fuentes LE, Algharably EAE, Schafer MS, Mangelsen E, Furtig MA, et al. Do \u03b2-blockers cause depression?: systematic review and meta-analysis of psychiatric adverse events during \u03b2-blocker therapy. Hypertension. 2021;77(5):1539\u201348. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16590.","journal-title":"Hypertension"},{"issue":"4","key":"2319_CR74","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.0000000000000315","volume":"35","author":"PI Georgianos","year":"2024","unstructured":"Georgianos PI, Agarwal R. Resistant hypertension in dialysis: epidemiology, diagnosis, and management. J Am Soc Nephrol. 2024;35(4):505\u201314. https:\/\/doi.org\/10.1681\/ASN.0000000000000315.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2319_CR75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1080\/08037051.2022.2110858","volume":"31","author":"M Esler","year":"2022","unstructured":"Esler M, Kjeldsen SE, Pathak A, Grassi G, Kreutz R, Mancia G. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Press. 2022;31(1):210\u201324. https:\/\/doi.org\/10.1080\/08037051.2022.2110858.","journal-title":"Blood Press"},{"issue":"3","key":"2319_CR76","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/sdi.12691","volume":"31","author":"MA Weir","year":"2018","unstructured":"Weir MA, Herzog CA. Beta blockers in patients with end-stage renal disease-evidence-based recommendations. Semin Dial. 2018;31(3):219\u201325. https:\/\/doi.org\/10.1111\/sdi.12691.","journal-title":"Semin Dial"},{"issue":"1","key":"2319_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00735-2","volume":"7","author":"H Chen","year":"2021","unstructured":"Chen H, Cao N, Wang L, Wu Y, Wei H, Li Y, et al. Biased activation of \u03b22-AR\/Gi\/GRK2 signal pathway attenuated \u03b21-AR sustained activation induced by \u03b21-adrenergic receptor autoantibody. Cell Death Discov. 2021;7(1):340. https:\/\/doi.org\/10.1038\/s41420-021-00735-2.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2319_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01855-z","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Hanada K, Staus DP, Makara MA, Dahal GR, Chen Q, et al. G\u03b1i is required for carvedilol-induced \u03b21 adrenergic receptor \u03b2-arrestin biased signaling. Nat Commun. 2017;8(1):1706. https:\/\/doi.org\/10.1038\/s41467-017-01855-z.","journal-title":"Nat Commun"},{"key":"2319_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041036","author":"L Gargiulo","year":"2020","unstructured":"Gargiulo L, Rivero EM, di Siervi N, Buzzi ED, Buffone MG, Davio CA, et al. Agonist effects of propranolol on non-tumor human breast cells. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9041036.","journal-title":"Cells"},{"issue":"6","key":"2319_CR80","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","volume":"79","author":"G Mancia","year":"2022","unstructured":"Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension guidelines. Hypertension. 2022;79(6):1153\u201366. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19020.","journal-title":"Hypertension"},{"key":"2319_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100475","volume":"13","author":"YH Ou","year":"2023","unstructured":"Ou YH, Tan A, Lee CH. Management of hypertension in obstructive sleep apnea. Am J Prev Cardiol. 2023;13:100475. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100475.","journal-title":"Am J Prev Cardiol"},{"issue":"21","key":"2319_CR82","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.015926","volume":"9","author":"C Lombardi","year":"2020","unstructured":"Lombardi C, Faini A, Mariani D, Gironi F, Castiglioni P, Parati G. Nocturnal arrhythmias and heart-rate swings in patients with obstructive sleep apnea syndrome treated with beta blockers. J Am Heart Assoc. 2020;9(21):e015926. https:\/\/doi.org\/10.1161\/JAHA.120.015926.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2319_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejvs.2009.02.019","volume":"38","author":"SC Paravastu","year":"2009","unstructured":"Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(1):66\u201370. https:\/\/doi.org\/10.1016\/j.ejvs.2009.02.019.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9","key":"2319_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005508.pub3","volume":"2013","author":"SC Paravastu","year":"2013","unstructured":"Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;2013(9):CD005508. https:\/\/doi.org\/10.1002\/14651858.CD005508.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2319_CR85","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/01.cir.72.6.1226","volume":"72","author":"WR Hiatt","year":"1985","unstructured":"Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation. 1985;72(6):1226\u201331. https:\/\/doi.org\/10.1161\/01.cir.72.6.1226.","journal-title":"Circulation"},{"issue":"2","key":"2319_CR86","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","volume":"58","author":"C Espinola-Klein","year":"2011","unstructured":"Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al. \u03b2-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148\u201354. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.169169.","journal-title":"Hypertension"},{"issue":"36","key":"2319_CR87","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700. https:\/\/doi.org\/10.1093\/eurheartj\/ehae179.","journal-title":"Eur Heart J"},{"issue":"24","key":"2319_CR88","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","volume":"149","author":"HL Gornik","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313\u2013410. https:\/\/doi.org\/10.1161\/CIR.0000000000001251.","journal-title":"Circulation"},{"issue":"46","key":"2319_CR89","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","volume":"41","author":"YL Yang","year":"2020","unstructured":"Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of \u03b2-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa793.","journal-title":"Eur Heart J"},{"issue":"5","key":"2319_CR90","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40256-025-00732-1","volume":"25","author":"R Xue","year":"2025","unstructured":"Xue R, Liu C, Yu Q, Dong Y, Zhao J. Appraisal of beta-blocker use in patients with cardiovascular disease and chronic obstructive pulmonary disease. Am J Cardiovasc Drugs. 2025;25(5):577\u201392. https:\/\/doi.org\/10.1007\/s40256-025-00732-1.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"2319_CR91","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/jcdd8090101","volume":"8","author":"D Masarone","year":"2021","unstructured":"Masarone D, Martucci ML, Errigo V, Pacileo G. The use of beta-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis. 2021;8(9):101. https:\/\/doi.org\/10.3390\/jcdd8090101.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"2","key":"2319_CR92","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MCP.0000000000000748","volume":"27","author":"FS Leitao Filho","year":"2021","unstructured":"Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021;27(2):125\u201331. https:\/\/doi.org\/10.1097\/MCP.0000000000000748.","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"2319_CR93","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s11255-023-03466-8","volume":"55","author":"H Dong","year":"2023","unstructured":"Dong H, Zhou L, Yang L, Lu H, Cao S, Song H, et al. \u03b2-blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study. Int Urol Nephrol. 2023;55(6):1597\u2013607. https:\/\/doi.org\/10.1007\/s11255-023-03466-8.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"2319_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279680","volume":"17","author":"TH Yeh","year":"2022","unstructured":"Yeh TH, Tu KC, Hung KC, Chuang MH, Chen JY. Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: a systematic review and meta-analysis. PLoS ONE. 2022;17(12):e0279680. https:\/\/doi.org\/10.1371\/journal.pone.0279680.","journal-title":"PLoS ONE"},{"issue":"1","key":"2319_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010373","volume":"25","author":"S Chinnappa","year":"2023","unstructured":"Chinnappa S, Maqbool A, Viswambharan H, Mooney A, Denby L, Drinkhill M. Beta blockade prevents cardiac morphological and molecular remodelling in experimental uremia. Int J Mol Sci. 2023;25(1):373. https:\/\/doi.org\/10.3390\/ijms25010373.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2319_CR96","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","volume":"13","author":"EL Fu","year":"2020","unstructured":"Fu EL, Uijl A, Dekker FW, Lund LH, Savarese G, Carrero JJ. Association between beta-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease. Circ Heart Fail. 2020;13(11):e007180. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007180.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"2319_CR97","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","volume":"58","author":"SV Badve","year":"2011","unstructured":"Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(11):1152\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2011.04.041.","journal-title":"J Am Coll Cardiol"},{"key":"2319_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n189","volume":"372","author":"A Albasri","year":"2021","unstructured":"Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021;372:n189. https:\/\/doi.org\/10.1136\/bmj.n189.","journal-title":"BMJ"},{"issue":"1","key":"2319_CR99","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","volume":"120","author":"Z Tian","year":"2024","unstructured":"Tian Z, Vollmer Barbosa C, Lang H, Bauersachs J, Melk A, Schmidt BMW. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024;120(1):108\u201319. https:\/\/doi.org\/10.1093\/cvr\/cvad165.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2319_CR100","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jsxmed\/qdae189","volume":"22","author":"Y Lu","year":"2025","unstructured":"Lu Y, Li L, Li Q, Sun G. Effect of nebivolol on erectile function: a systematic review and meta-analysis of randomized controlled trials. J Sex Med. 2025;22(2):307\u201316. https:\/\/doi.org\/10.1093\/jsxmed\/qdae189.","journal-title":"J Sex Med"},{"issue":"8","key":"2319_CR101","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1097\/HJH.0000000000001777","volume":"36","author":"C Thomopoulos","year":"2018","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637\u201347. https:\/\/doi.org\/10.1097\/HJH.0000000000001777.","journal-title":"J Hypertens"},{"issue":"9","key":"2319_CR102","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/HJH.0000000000002523","volume":"38","author":"C Thomopoulos","year":"2020","unstructured":"Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens. 2020;38(9):1669\u201381. https:\/\/doi.org\/10.1097\/HJH.0000000000002523.","journal-title":"J Hypertens"},{"issue":"6","key":"2319_CR103","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/HJH.0000000000003735","volume":"42","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, Kjeldsen SE, et al. Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern. J Hypertens. 2024;42(6):966\u20137. https:\/\/doi.org\/10.1097\/HJH.0000000000003735.","journal-title":"J Hypertens"},{"issue":"9","key":"2319_CR104","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/pds.4808","volume":"28","author":"SJ Sinnott","year":"2019","unstructured":"Sinnott SJ, Smeeth L, Williamson E, Perel P, Nitsch D, Tomlinson LA, et al. The comparative effectiveness of fourth-line drugs in resistant hypertension: an application in electronic health record data. Pharmacoepidemiol Drug Saf. 2019;28(9):1267\u201377. https:\/\/doi.org\/10.1002\/pds.4808.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2319_CR105","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1161\/HYPERTENSIONAHA.122.19280","volume":"79","author":"R Desai","year":"2022","unstructured":"Desai R, Park H, Brown JD, Mohandas R, Pepine CJ, Smith SM. Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension. Hypertension. 2022;79(10):2305\u201315. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19280.","journal-title":"Hypertension"},{"issue":"10008","key":"2319_CR106","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3.","journal-title":"Lancet"},{"issue":"4","key":"2319_CR107","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"EM Krieger","year":"2018","unstructured":"Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension. 2018;71(4):681\u201390. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10662.","journal-title":"Hypertension"},{"issue":"4","key":"2319_CR108","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejheart.2004.01.015","volume":"6","author":"UC Hoppe","year":"2004","unstructured":"Hoppe UC. Beta-blocker induced bradycardia\u2013Should we pace? Eur J Heart Fail. 2004;6(4):449\u201351. https:\/\/doi.org\/10.1016\/j.ejheart.2004.01.015.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2319_CR109","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s0002-9394(02)01699-9","volume":"134","author":"PJ Lama","year":"2002","unstructured":"Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749\u201360. https:\/\/doi.org\/10.1016\/s0002-9394(02)01699-9.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2319_CR110","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/HJH.0000000000003130","volume":"40","author":"ML Alimento","year":"2022","unstructured":"Alimento ML, Palermo P, Italiano G, Antonioli L, Salvioni E, Agostoni P. Can beta-blockers influence regular daily physical activity? J Hypertens. 2022;40(6):1199\u2013203. https:\/\/doi.org\/10.1097\/HJH.0000000000003130.","journal-title":"J Hypertens"},{"issue":"10313","key":"2319_CR111","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(21)01920-6.","journal-title":"Lancet"},{"key":"2319_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1489657","volume":"15","author":"S Drygala","year":"2024","unstructured":"Drygala S, Radzikowski M, Maciejczyk M. \u03b2-blockers and metabolic modulation: unraveling the complex interplay with glucose metabolism, inflammation and oxidative stress. Front Pharmacol. 2024;15:1489657. https:\/\/doi.org\/10.3389\/fphar.2024.1489657.","journal-title":"Front Pharmacol"},{"key":"2319_CR113","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07753-7","author":"S Gazit","year":"2025","unstructured":"Gazit S, Yonatan Y, Hoshen MB, Mahfoud F, Patalon TT. Effect of bisoprolol versus other beta-blockers on glycemic control and metabolic parameters in type 2 diabetes: a retrospective cohort study. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07753-7.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"347","key":"2319_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6745","volume":"9","author":"L Shen","year":"2013","unstructured":"Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, et al. Role of diuretics, beta blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;9(347):f6745. https:\/\/doi.org\/10.1136\/bmj.f6745.","journal-title":"BMJ"},{"issue":"3","key":"2319_CR115","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01541742","volume":"17","author":"RC Rosen","year":"1988","unstructured":"Rosen RC, Kostis JB, Jekelis AW. Beta-blocker effects on sexual function in normal males. Arch Sex Behav. 1988;17(3):241\u201355. https:\/\/doi.org\/10.1007\/BF01541742.","journal-title":"Arch Sex Behav"},{"key":"2319_CR116","doi-asserted-by":"crossref","unstructured":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981;2(8246):539\u201343","DOI":"10.1016\/S0140-6736(81)90936-3"},{"key":"2319_CR117","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2025.08.005","volume":"291","author":"PV Rasmussen","year":"2026","unstructured":"Rasmussen PV, Strange JE, Nielsen SK, Hansen RB, Gislason GH, Lamberts M, et al. Beta-blocker side-effects in clinical practice: a nationwide approach. Am Heart J. 2026;291:111\u201320. https:\/\/doi.org\/10.1016\/j.ahj.2025.08.005.","journal-title":"Am Heart J"},{"key":"2319_CR118","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18596","volume":"12","author":"M Rashidi","year":"2024","unstructured":"Rashidi M, Kiskac N, Kaya Meral D, Cakmak S, Durusoy E, Nart A, et al. Assessment of erectile dysfunction prevalence and associated factors in hypertensive men. PeerJ. 2024;12:e18596. https:\/\/doi.org\/10.7717\/peerj.18596.","journal-title":"PeerJ"},{"issue":"21","key":"2319_CR119","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.ehj.2003.08.016","volume":"24","author":"A Silvestri","year":"2003","unstructured":"Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928\u201332. https:\/\/doi.org\/10.1016\/j.ehj.2003.08.016.","journal-title":"Eur Heart J"},{"key":"2319_CR120","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag022","author":"S Taddei","year":"2026","unstructured":"Taddei S, Narkiewicz K, Bricout-Hennel S, Petrova P, Batailler C, Asmar R. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. Eur Heart J. 2026. https:\/\/doi.org\/10.1093\/eurheartj\/ehag022.","journal-title":"Eur Heart J"},{"issue":"7","key":"2319_CR121","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ajh\/hpad013","volume":"36","author":"G Bourque","year":"2023","unstructured":"Bourque G, Ilin JV, Ruzicka M, Hundemer GL, Shorr R, Hiremath S. Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta-analysis. Am J Hypertens. 2023;36(7):394\u2013403. https:\/\/doi.org\/10.1093\/ajh\/hpad013.","journal-title":"Am J Hypertens"},{"issue":"6","key":"2319_CR122","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","volume":"38","author":"AJ Lawson","year":"2020","unstructured":"Lawson AJ, Hameed MA, Brown R, Cappuccio FP, George S, Hinton T, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38(6):1165\u201373. https:\/\/doi.org\/10.1097\/HJH.0000000000002398.","journal-title":"J Hypertens"},{"issue":"4","key":"2319_CR123","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766\u201374. https:\/\/doi.org\/10.1097\/HJH.0b013e32835e2286.","journal-title":"J Hypertens"},{"issue":"4","key":"2319_CR124","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/08964289.2025.2503201","volume":"51","author":"PJ Highton","year":"2025","unstructured":"Highton PJ, Funnell MP, Lane D, Vigneswara V, Jenkins S, Kacha G, et al. Chemical adherence testing for assessing adherence to antihypertensive medications: a systematic review and meta-analysis of prevalence of nonadherence. Behav Med. 2025;51(4):265\u201379. https:\/\/doi.org\/10.1080\/08964289.2025.2503201.","journal-title":"Behav Med"},{"issue":"1","key":"2319_CR125","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41440-024-01988-x","volume":"48","author":"CJ Lee","year":"2025","unstructured":"Lee CJ, Lee H, Seo J, Hwang J, Kang D, Park SH, et al. Prognosis of apparent treatment-resistant hypertension and poor adherence: a nationwide cohort study. Hypertens Res. 2025;48(1):49\u201359. https:\/\/doi.org\/10.1038\/s41440-024-01988-x.","journal-title":"Hypertens Res"},{"issue":"7","key":"2319_CR126","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jch.14517","volume":"24","author":"P Danaietash","year":"2022","unstructured":"Danaietash P, Verweij P, Wang JG, Dresser G, Kantola I, Lawrence MK, et al. Identifying and treating resistant hypertension in PRECISION: a randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022;24(7):804\u201313. https:\/\/doi.org\/10.1111\/jch.14517.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10293","key":"2319_CR127","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1.","journal-title":"Lancet"},{"issue":"7","key":"2319_CR128","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/bcp.15292","volume":"89","author":"JMG Curneen","year":"2023","unstructured":"Curneen JMG, Rabbitt L, Browne D, O\u2019Donoghue DF, Alansari Y, Harhen B, et al. Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: a prospective study in a tertiary-referral hypertension clinic. Br J Clin Pharmacol. 2023;89(7):1948\u201355. https:\/\/doi.org\/10.1111\/bcp.15292.","journal-title":"Br J Clin Pharmacol"},{"key":"2319_CR129","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.2147\/PPA.S368784","volume":"16","author":"SM Hamrahian","year":"2022","unstructured":"Hamrahian SM, Maarouf OH, F\u00fcl\u00f6p T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence. 2022;16:2749\u201357. https:\/\/doi.org\/10.2147\/PPA.S368784.","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"2319_CR130","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/jch.14041","volume":"22","author":"C LaVallee","year":"2020","unstructured":"LaVallee C, Rascati KL, Gums TH. Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States. J Clin Hypertens (Greenwich). 2020;22(11):2084\u201392. https:\/\/doi.org\/10.1111\/jch.14041.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10208","key":"2319_CR131","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)32135-X.","journal-title":"Lancet"},{"issue":"8","key":"2319_CR132","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326. https:\/\/doi.org\/10.1002\/ejhf.1199.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2319_CR133","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ehf2.14137","volume":"10","author":"J Henrysson","year":"2023","unstructured":"Henrysson J, Thunstrom E, Chen X, Fu M, Basic C. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure. ESC Heart Fail. 2023;10(1):66\u201379. https:\/\/doi.org\/10.1002\/ehf2.14137.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"2319_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2022-002022","volume":"9","author":"A Jonsson Holmdahl","year":"2022","unstructured":"Jonsson Holmdahl A, Wessberg G, Norberg H, Soderstrom A, Valham F, Bergdahl E, et al. Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. Open Heart. 2022;9(2):e002022. https:\/\/doi.org\/10.1136\/openhrt-2022-002022.","journal-title":"Open Heart"},{"issue":"2","key":"2319_CR135","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16(2):293\u2013302. https:\/\/doi.org\/10.1093\/ckj\/sfac234.","journal-title":"Clin Kidney J"},{"key":"2319_CR136","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.127.","journal-title":"Int J Cardiol"},{"issue":"46","key":"2319_CR137","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","volume":"24","author":"MS Kallistratos","year":"2018","unstructured":"Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des. 2018;24(46):5537\u201341. https:\/\/doi.org\/10.2174\/1381612825666190222144359.","journal-title":"Curr Pharm Des"},{"issue":"12","key":"2319_CR138","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","volume":"30","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat Med. 2024;30(12):3634\u201345. https:\/\/doi.org\/10.1038\/s41591-024-03263-5.","journal-title":"Nat Med"},{"issue":"6","key":"2319_CR139","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"issue":"16","key":"2319_CR140","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"issue":"10","key":"2319_CR141","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jch.14699","volume":"25","author":"C Darricarrere","year":"2023","unstructured":"Darricarrere C, Jacquot E, Bricout S, Louis C, B\u00e9nard M, Poulter NR. Uncontrolled blood pressure and therapeutic inertia in treated hypertensive patients: a retrospective cohort study using a UK general practice database. J Clin Hypertens (Greenwich). 2023;25(10):895\u2013904. https:\/\/doi.org\/10.1111\/jch.14699.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"740","key":"2319_CR142","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3399\/bjgp24X736390","volume":"74","author":"T McCormack","year":"2024","unstructured":"McCormack T, Partridge S, Wilkinson I. Specialist hypertension clinics: an essential pathway but under-resourced. Br J Gen Pract. 2024;74(740):100\u20132. https:\/\/doi.org\/10.3399\/bjgp24X736390.","journal-title":"Br J Gen Pract"},{"issue":"1","key":"2319_CR143","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5334\/aogh.4246","volume":"90","author":"S Byiringiro","year":"2024","unstructured":"Byiringiro S, Hinneh T, Chepkorir J, Tomiwa T, Commodore-Mensah Y, Marsteller J, et al. Healthcare system barriers and facilitators to hypertension management in Ghana. Ann Glob Health. 2024;90(1):38. https:\/\/doi.org\/10.5334\/aogh.4246.","journal-title":"Ann Glob Health"},{"issue":"1","key":"2319_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-022-00285-7","volume":"74","author":"G Youssef","year":"2022","unstructured":"Youssef G, Mohamed M, Abdel Hamid M, El Remisy D. Reasons behind high rate of non-compliance to scheduled office visits in hypertensive patients: results from the Egyptian registry of specialized hypertension clinics. Egypt Heart J. 2022;74(1):45. https:\/\/doi.org\/10.1186\/s43044-022-00285-7.","journal-title":"Egypt Heart J"},{"issue":"1","key":"2319_CR145","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340. https:\/\/doi.org\/10.1530\/JOE-16-0600.","journal-title":"J Endocrinol"},{"issue":"23","key":"2319_CR146","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"issue":"12","key":"2319_CR147","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758\u201364. https:\/\/doi.org\/10.1038\/s41591-024-03264-4.","journal-title":"Nat Med"},{"issue":"31","key":"2319_CR148","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043615","volume":"104","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan ABM, Mondal S, Nagendra L, Dutta D, Bhattacharya S, Pappachan JM. Safety of esaxerenone (CS-3150) and its impacts on blood pressure and renal function: a systematic review and meta-analysis. Medicine (Baltimore). 2025;104(31):e43615. https:\/\/doi.org\/10.1097\/MD.0000000000043615.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2319_CR149","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70094","volume":"8","author":"JS Goh","year":"2025","unstructured":"Goh JS, Sohail S, Ayub H, Cheema ZZ, Paray NB, Adikari S, et al. Efficacy and safety of aldosterone synthase inhibitors in hypertension: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2025;8(5):e70094. https:\/\/doi.org\/10.1002\/edm2.70094.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"14","key":"2319_CR150","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393(14):1363\u201374. https:\/\/doi.org\/10.1056\/NEJMoa2507109.","journal-title":"N Engl J Med"},{"issue":"5","key":"2319_CR151","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez Fernandez B, Ghali JK, Kopjar B, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the launch-HTN randomized clinical trial. JAMA. 2025;334(5):409\u201318. https:\/\/doi.org\/10.1001\/jama.2025.9413.","journal-title":"JAMA"},{"issue":"10367","key":"2319_CR152","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7.","journal-title":"Lancet"},{"key":"2319_CR153","unstructured":"Idorsia Pharmaceuticals Deutschland GmbH. Jeraygo (aprocitentan) Summary of Product Characteristics. July 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jeraygo-epar-product-information_en.pdf."},{"issue":"2","key":"2319_CR154","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","volume":"108","author":"M Esler","year":"2010","unstructured":"Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (1985). 2010;108(2):227\u201337. https:\/\/doi.org\/10.1152\/japplphysiol.00832.2009.","journal-title":"J Appl Physiol (1985)"},{"issue":"9","key":"2319_CR155","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/eurheartj\/ehs041","volume":"33","author":"G Parati","year":"2012","unstructured":"Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058\u201366. https:\/\/doi.org\/10.1093\/eurheartj\/ehs041.","journal-title":"Eur Heart J"},{"issue":"8","key":"2319_CR156","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1097\/HJH.0000000000002407","volume":"38","author":"M Esler","year":"2020","unstructured":"Esler M, Lambert G, Esler D, Ika Sari C, Guo L, Jennings G. Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension. J Hypertens. 2020;38(8):1488\u201395. https:\/\/doi.org\/10.1097\/HJH.0000000000002407.","journal-title":"J Hypertens"},{"issue":"6","key":"2319_CR157","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00004872-199917060-00001","volume":"17","author":"G Grassi","year":"1999","unstructured":"Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17(6):719\u201334. https:\/\/doi.org\/10.1097\/00004872-199917060-00001.","journal-title":"J Hypertens"},{"issue":"6","key":"2319_CR158","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCRESAHA.116.303604","volume":"116","author":"G Grassi","year":"2015","unstructured":"Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976\u201390. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303604.","journal-title":"Circ Res"},{"issue":"3","key":"2319_CR159","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"},{"key":"2319_CR160","unstructured":"Press release: KARDIA-3 trial examines blood-pressure lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk. 2025. https:\/\/www.escardio.org\/news\/press\/press-releases\/KARDIA-3-trial-examines-blood-pressure-lowering-effects-of-zilebesiran-in-hypertensive-patients-at-high-cardiovascular-risk\/. [cited March 3, 2026]"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02319-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02319-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02319-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:20Z","timestamp":1778856020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02319-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":160,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2319"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02319-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sofie BROUWERS has received honoraria for consultancy or lectures from Daiichi Sankyo, Novartis, Amgen, Recor, Servier, and Medtronic. Rosa Maria BRUNO has received speaker\u2019s honoraria\u00a0from Medtronic, Servier, El Kendi, and LXO. Reinhold KREUTZ has received honoraria for consultancy or lectures from AstraZeneca, Bayer, Krka, Menarini Group, Merck, ProMed, PolPharma, Recor, Servier, and Zentiva. Stefano MASI has received consultation fees and honoraria for lectures, editorial activities, and advisory board participation from Servier. Krzysztof NARKIEWICZ has received honoraria for consultancy or lectures from AstraZeneca, Bausch, Berlin-Chemie\/Menarini, Egis, Eli Lilly, Gedeon Richter, Krka, Medtronic, Novo Nordisk, Omron, Polpharma, Promed, Recordati, Sandoz, Servier, and Zentiva. Atul PATHAK has received honoraria for consultancy or lectures from AstraZeneca, Bayer, Medtronic, Merck, Novartis, Recor, and Servier. Stefano TADDEI has received honoraria for consultancy or lectures from Servier, Pfizer, Merck Serono, Sandoz, Neopharmed, Sharper, and Medtronic. Konstantinos TSIOUFIS has received research grants from Recor, Medtronic, and Recordatti and honoraria for consultancy or lectures from Medtronic, Servier, Bayer, Menarini, Novartis, AstraZeneca, Boehringer In, Pfizer, Chiesi, Pharmanel, Sanofi, Amgen, VIATRIS, and HIKMA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception, design and writing of the review. All authors reviewed, edited, approved the final manuscript, and ensured the accuracy and integrity of the cited content.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}